Global T Cell Lymphoma Market & Clinical Pipeline Insight

Global T Cell Lymphoma Market & Clinical Pipeline Insight

  • March 2016 •
  • 168 pages •
  • Report ID: 4397198 •
  • Format: PDF
Immune system consists of various cells that impart resistance to body against foreign entities. They also prevent the development of aberrant cells in the body to maintain its normal functioning. However, it has been noted that these cells are also liable for deterioration leading to diseases development. For instance, T-cell lymphoma is cancer causing unrestricted growth of T-cells leading to impaired immune system. Investigators have identified different T-cell malignancies that cause high morbidity and mortality. As a result, several cancer therapeutics have been developed in past years to prevent T-cell lymphoma proliferation and progression.

T-cell lymphoma is divided into several disease segments based on their pathophysiology that causes difficulty in identification and treatment. Most of the therapeutics have been developed for the Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL) which affects blood and skin, respectively. Other subcategories of T-cell lymphoma are largely untouched due to which large unmet necessities could be observed. For instance, Adult T-cell lymphoma is found in 2%-5% patients suffering from Human T-Lymphotropic Viruses, type I (HTLV-1) infection. Generally chemotherapeutics approaches are used which have modest safety and efficacy profiles. As a result, appropriate therapeutics is not available leading to high unmet medical necessities giving emphasis on development of innovative modalities for T-cell lymphoma treatment.

With time, new modalities are expected to be developed as underlying principles behind T-cell lymphoma would be deciphered. For instance, investigators developed extracorporeal photopheresis as an advanced method that could improve survival in patients. Low toxicity and activation of treatment on demand are among one of the most sought features. This procedure could also be used with other therapeutics to achieve better pharmacological effects. Despite these benefits, its utility is limited because of special procedure requiring patients to stay in hospital for T-cell lymphoma treatment. This scenario indicates that more research and development is required for new and improved T-cell lymphoma therapeutics. Some of the progress has been made by developing immunotoxin, HDAC inhibitors, monoclonal antibodies and other investigational therapeutics.

Technological advancements are expected to help the investigators to develop better therapeutics and increase the discovery rates. Increased investments in research and development are expected to help in development of better therapeutic with superior pharmacological and commercialization potential. They are expected to offer severe competition to existing therapeutics due to which more revenues are expected to be generated. Lots of opportunity are available as myriad of candidates with different biological properties are under T-cell lymphoma clinical trials. Cancer market is expected to witness introduction of several innovative products which will help the pharmaceutical companies to generate significant revenues. These products are at different stages of clinical trials due to which they would take some time before entering in global market. In this way, future T-cell lymphoma therapeutics looks optimistic due to their superior pharmacological profiles.